Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...
Iovance Biotherapeutics recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its 2024 earnings ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed last Friday at ...
Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents. In the year-ago quarter, the company ...
Shares of NASDAQ:IOVA opened at $4.04 on Monday. The firm has a market cap of $1.23 billion, a PE ratio of -2.71 and a beta of 0.53. The firm’s 50 day simple moving average is $6.21 and its 200 ...
NASDAQ:IOVA opened at $4.24 on Monday. The firm has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $8.55. Iovance Biotherapeutics has a twelve month low of $3 ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Iovance Biotherapeutics (IOVA – Research Report), Xencor (XNCR – Research Report) and Merus ...
The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...
Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results